Amy W. Schulman
Ms. Schulman is a Venture Partner at Polaris Partners, serves as CEO of Arsia Therapeutics, an early stage biotech company, and is Executive Chair of SQZ Biotech. Ms. Schulman is also a senior lecturer at Harvard Business School. Prior to these roles, Ms. Schulman was General Counsel, EVP, and the Business Unit Lead for Pfizer’s Consumer Healthcare business. Before joining Pfizer, she was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees. Ms. Schulman is the recipient of numerous awards and accolades including Fortune‘s 50 Most Powerful Women in Business 2013, The American Lawyer’s Top 50 Innovators 2013, and the Margaret Brent Women Lawyers Achievement Award from the American Bar Association in 2012. She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School in 1989. Ms. Schulman serves on the Board of Directors of Alnylam Pharmaceuticals, BIND Therapeutics, Blue Buffalo, The Brookings Institution, and Wesleyan University.